Event: 'BIGs (Business Interface Groups): Technology Showcase + Lifescience - Drugs, Bugs & Devices'
Date: Thursday, January 18, 2007 At 06:00
Duration: 2 Hours 30 Minutes
Cooley Godward LLP 3175 Hanover Street Palo Alto, CA 94304 Contact: Laura Weigant Email: [email protected]
Innovation in the Life Science industry continues at an accelerating pace and a number of important trends are taking root, ranging from integrated devices that deliver drugs, to health systems to stem-cell therapies.
What will set the tone and trends that affect the ability to attract financing in 2007?
Investor panelists will gaze the crystal ball and foretell what is going to be hot in 2007 in the Life Science sector. They will explain how startup opportunities are analyzed to yield an investment decision. This event will also include suggestions on how to structure your pitch to ensure that you keep your audience focused in 2007.
Will your startup measure up, or not, in the coming year?
This lively panel discussion will explore current trends and panelist opinions on topics including:
• Who is getting a healthy infusion of cash?
• How much money is sitting on the sidelines, waiting to be invested?
• What is happening inside the mind of the investors?
• What's Hot/What's Not in Biotech, Medical Devices and Healthcare Sectors?
• Is Biotech still getting the lion’s share of interest, valuations and glamour?
• How much will be available for seed and early stage investments?
This experienced panel, who are leading investors in the Life Sciences, will discuss current trends in the Life Science sector and share their experience and insights about what is the shape of things to come in 2007.
• Lou Bock, Managing Director, Bank of America Ventures
• Karen Boezi, Co-Founder & Partner, Thomas, McNerney & Partners
• Richard Ferrari, Managing Director, De Novo Ventures
• Camille Samuels Pearson, Managing Director, Versant Ventures
Moderator: Frank Rahmani, Partner, Cooley Godward Kronish
When: Thursday, January 18
6:00-7:00 pm: Networking & Technology Showcase
7:00-8:00 pm: Panel discussion and Q/A
8:00-8:30 pm: More networking
Cooley Godward LLP, 3175 Hanover Street, Palo Alto, CA 94304
PRE-REGISTERED RATES (All Rates Include Hors D’oeuvres):
Members - $20; Affiliates who advertise this event - $29; General Public - $49; Technology Showcase Exhibit Table: $149 (Includes Exhibit table and two tickets to the event).
WALK-IN RATES: Add $10.00 to the listed price
Seating is limited, so early registration is recommended to avoid disappointment on the day.
This event is co-sponsored by Cooley Godward Kronish LLP, www.cooley.com
Karen M. Boezi, Co-Founder & Partner, Thomas, McNerney & Partners
Karen is a co-founder of Thomas, McNerney & Partners and has over 15 years of experience investing in health care companies. She is currently a board member of Leptos Biomedical, Inc., Ocera Therapeutics, Inc. and NaviMedix, Inc. Previous investments include Coulter Pharmaceutical, Inc. (CLTR sold to CRXA which was subsequently sold to GSK), Endocardial Solutions, Inc. (ECSI sold to STJ), Epicor Medical, Inc. (sold to STJ) and NeXagen, Inc. (NXGN/NXTR sold to GILD with spin-outs to EYET, Archemix and SomaLogic). Karen joined Coral Ventures in 1994 where she became a General Partner and managed the firm’s West Coast office. Previously, Karen was a member of Warburg Pincus LLC’s medical technology venture capital group. While at Warburg, she focused on seed stage investments in the life science industry and was the start-up manager for two biotechnology companies, including NeXagen, Inc. Prior to joining Warburg in 1990, Karen was an analyst in the health care corporate finance department at Alex. Brown & Sons, Inc.
Karen graduated Phi Beta Kappa and magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania. She is currently a member of The Permanente Company LLC’s Board of Directors and founded the West Coast Chapter of the Wharton Private Equity Network.
Lou Bock, Band America Venture PartnersAs excited as he gets about new technologies and therapeutic possibilities, Lou Bock believes that a drug development company's most important asset is its management team. With more than 15 years of industry experience, Lou knows that the defining moments of market traction come early in healthcare.
At BAVP, Lou helps biopharmaceutical, device and platform technology companies build strong management teams and maximize the value of every round of capital. He brings considerable biotech business experience and industry smarts to the critical challenges of clinical development strategy and management. Lou sits on the boards of Ascenta Therapeutics, diaDexus, Inc., Orexigen Therapeutics, SGX Pharmaceuticals and Somaxon Pharmaceuticals. He is responsible for investments in Dynavax Technologies (Nasdaq: DVAX), Seattle Genetics (Nasdaq: SGEN) and Prestwick Pharmaceuticals and Zogenix.
Lou joined BAVP in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide and was responsible for the discovery of Gilead's novel anticoagulant, GS-522. This anticoagulant, now referred to as ARC-183, is being developed jointly by Archemix/Nuvelo and is in Phase I clinical trials. Previous to Gilead, he was a research associate at Genentech.
Lou holds a BS in Biology from California State University, Chico and an MBA from California State University, San Francisco.
Richard Ferrari, De Novo Ventures
Mr. Ferrari was the co-founder and CEO of CardioThoracic Systems, a company he led to an initial public offering in 1996. CTSI was ultimately acquired by Guidant Corporation in November 1999. In addition, he founded Saratoga Ventures, a venture capital partnership that has provided seed funding to startup medical technology companies. At Saratoga, Mr. Ferrari was Chairman of Oratec, which was sold in 2001 to Smith & Nephew PLC. Prior to that, Mr. Ferrari was the CEO of a publicly traded medical technology company, Cardiovascular Imaging Systems. CVIS was acquitted by Boston Scientific Corporation in 1995. Mr. Ferrari also co-founded The Medical Technology Group, which spun out Integrated Vascular Systems, a company which was sold to Abbott. From 1986 to 1990, Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories.
He holds a BS degree from Ashland University and an MBA from the University of South Florida.
Camille Samuels Pearson, Versant Ventures
Camille Samuels specializes in biotechnology investing at Versant. Camille joined Versant in early 2000, shortly after its formation.
Prior to Versant, Camille was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Camille worked in business development/strategic planning at Genzyme and Millennium Predictive Medicine, and as a management consultant to healthcare and biotech companies at LEK Consulting.
Camille currently serves as a board member of the following private companies: Achaogen, Kythera, Novacardia, as well as Novacea (NOVC), a public company. Camille was previously a board observer at several companies, including 5 AM, Alexza (public), Genomic Health (public) and Syrrx (sold) as well as Pathwork Diagnostics (formerly Predicant Biosciences).
Camille earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.
Frank F. Rahmani, Cooley Godward Kronish
Frank Rahmani is a partner in the Cooley Godward Kronish Business department. Resident in the Palo Alto office, he has been with the Firm since 1997.
Mr. Rahmani has a general business and corporate law practice with an emphasis in the representation of emerging growth companies, intellectual property transactions, securities transactions, including private and public financing, and mergers and acquisitions.
Mr. Rahmani has counseled companies, entrepreneurs and investors in a broad range of matters including start-up formation and spin-off transactions, assistance with obtaining early stage financing, technology acquisition and licensing matters, to later stage financings, strategic and commercial relationships, variety of public offerings and mergers and acquisitions.
Mr. Rahmani counsels companies in a wide range of industries including medical devices and life sciences, software, semiconductor and telecommunication equipment.
Mr. Rahmani received a J.D., from Santa Clara University School of Law in 1997, where he was on the Deans' List and was a representative to the American Bar Association. He received a business degree from Santa Clara University.
Prior to joining Cooley, Mr. Rahmani was an analyst with Intel Corporation working with the corporate finance and worldwide sales organizations.
Mr. Rahmani is a member of the State Bar of California.
• Santa Clara University School of Law
• Santa Clara University
Added by svaseinfo on December 16, 2006